Medicxi

Portfolio Companies 2026 for Medicxi: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Medicxi accounts for 11 tracked companies with verified cap-table data, 11 of which disclose round sizes totalling $1.3B. The median disclosed raise is $100M, and the largest is D3 Bio at $308M, ahead of Curevo ($192M) and Rivus Pharmaceuticals ($167M).

The names that recur most often on these portfolio cap tables are Medicxi (11 companies), RA Capital Management (3 companies), Forbion (2 companies), IDG Capital (1 company), SongQing Capital (1 company), WuXi AppTec's Corporate Venture Fund (1 company). By latest disclosed round, the market skews Series B (7), Series A (2), Seed (1), Series D (1).

Best funded Medicxi companies

  1. D3 Bio — $308M (latest: Series B)
  2. Curevo — $192M (latest: Series B)
  3. Rivus Pharmaceuticals — $167M (latest: Series B)
  4. Ottimo Pharma — $140M (latest: Series A)
  5. Alys Pharmaceuticals — $100M (latest: Seed)
  6. Vicebio — $100M (latest: Series B)
  7. SynOx Therapeutics — $92M (latest: Series B)
  8. Altesa — $79M (latest: Series B)
  9. Versanis Bio — $70M (latest: Series A)
  10. Aura Biosciences — $40M (latest: Series D)
  11. Xenikos — $30M (latest: Series B)

Medicxi — related firms and companies (54)

Medicxi alternatives · All research reports